​

Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LXRX Stock Forecast

Lexicon Pharmaceuticals (LXRX) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 248.84% increase from the last price of $1.72.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $1.72

LXRX Stock Rating

Lexicon Pharmaceuticals stock's rating consensus is Hold, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (35.71%), 7 Hold (50.00%), 2 Sell (14.29%), and 0 Strong Sell (0.00%).

Hold
Total 14 0 2 7 5 Strong Sell Sell Hold Buy Strong Buy

LXRX Price Target Upside V Benchmarks

TypeNameUpside
StockLexicon Pharmaceuticals248.84%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.72$1.72$1.72
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26122--5
Feb, 26122--5
Jan, 26122--5
Dec, 25122--5
Nov, 25212--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 18, 2024Roanna RuizLeerink Partners$6.00$2.01198.51%248.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2026H.C. WainwrightBuyBuyhold
Jan 14, 2026CitigroupBuyBuyhold
Mar 07, 2025Piper SandlerOverweightOverweighthold
Oct 23, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Leerink PartnersOutperformOutperformhold
Oct 17, 2024Piper SandlerOverweightOverweighthold
Sep 27, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Aug 02, 2024H.C. WainwrightBuyBuyhold
Jun 17, 2024H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.61$-0.62$-0.80$-0.63$-0.14---
Avg Forecast$-0.61$-0.56$-0.80$-0.68$-0.46$-0.41$-0.30$-0.08
High Forecast$-0.43$-0.15$-0.78$-0.59$-0.32$-0.26$-0.18$-0.02
Low Forecast$-0.87$-1.71$-0.81$-0.76$-0.67$-0.68$-0.39$-0.22
Surprise %-10.71%--7.35%-69.57%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$298.00K$139.00K$1.20M$31.08M$49.80M---
Avg Forecast$194.67K$137.00K$1.75M$11.13M$13.33M$26.92M$94.86M$188.72M
High Forecast$261.29K$352.10K$1.87M$26.90M$29.25M$26.92M$235.47M$468.45M
Low Forecast$150.31K$60.61K$1.62M$5.59M$5.45M$26.92M$37.10M$73.80M
Surprise %53.08%1.46%-31.26%179.22%273.65%---

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-87.76M$-101.94M$-177.12M$-200.40M$-50.34M---
Avg Forecast$-96.45M$-97.36M$-177.12M$-149.02M$-109.19M$-104.28M$-62.60M$-16.95M
High Forecast$-77.16M$-77.89M$-141.70M$-129.68M$-70.52M$-57.93M$-39.75M$-3.53M
Low Forecast$-115.74M$-116.83M$-212.54M$-168.35M$-147.86M$-150.62M$-85.46M$-49.62M
Surprise %-9.01%4.71%-34.49%-53.89%---

LXRX Forecast FAQ

Is Lexicon Pharmaceuticals stock a buy?

Lexicon Pharmaceuticals stock has a consensus rating of Hold, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 7 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Lexicon Pharmaceuticals is a neutral investment for most analysts.

What is Lexicon Pharmaceuticals's price target?

Lexicon Pharmaceuticals's price target, set by 14 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 248.84% change from the previous closing price of $1.72.

How does Lexicon Pharmaceuticals stock forecast compare to its benchmarks?

Lexicon Pharmaceuticals's stock forecast shows a 248.84% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Lexicon Pharmaceuticals over the past three months?

  • March 2026: 20.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 20.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.

What is Lexicon Pharmaceuticals’s EPS forecast?

Lexicon Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.41, marking a 192.86% increase from the reported $-0.14 in 2025. Estimates for the following years are $-0.3 in 2027, and $-0.08 in 2028.

What is Lexicon Pharmaceuticals’s revenue forecast?

Lexicon Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $26.92M, reflecting a -45.94% decrease from the reported $49.8M in 2025. The forecast for 2027 is $94.86M, and $188.72M for 2028.

What is Lexicon Pharmaceuticals’s net income forecast?

Lexicon Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-104M, representing an 107.14% increase from the reported $-50.341M in 2025. Projections indicate $-62.603M in 2027, and $-16.953M in 2028.